Gos­samer’s Fa­heem Has­nain de­fends a round of pos­i­tive PAH da­ta as a clear win. But can these PhII re­sults stand up to scruti­ny?

Gos­samer Bio $GOSS post­ed a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment for its pri­ma­ry end­point in the key Phase II TOR­REY tri­al for lead drug ser­a­lu­tinib on Tues­day …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN